Two pioneering molecular tests which can quickly detect Covid-19, influenza and respiratory infections have been developed by NIPD Genetics and are now available in Cyprus and abroad, the Nicosia-based medical laboratory announced on Tuesday.
The tests are being made available at a time considered critical by scientists, the laboratory said, as it is believed the current Covid-19 pandemic will continue to co-exist with other seasonal respiratory infections which have similar symptoms, which makes their diagnosis very difficult.
“NIPD Genetics has developed and is offering four respiratory virus controls, a new molecular test that simultaneously detects the new SARS-CoV-2 coronavirus that causes Covid-19, the Influenza A and B viruses that cause the common flu, as well as the Respiratory Syndrome (RSV) virus, which causes RSV respiratory infection.”
According to the press release, both the common flu viruses and RSV cause annual outbreaks during the autumn and winter months. Therefore, they are expected to coexist with the SARS-CoV-2 coronavirus pandemic.
“Due to the many similarities between the symptoms and the transmission of these diseases, it is important to distinguish whether the infection is caused by the new coronavirus or other viruses, so that those affected can receive appropriate treatment and take the necessary measures. isolation and protection.”
NIPD Genetics also offers 22 Respiratory Infections Control, which looks at 22 different pathogens, including SARS-COV-2, Influenza A and B, RSV, and many other viruses and bacteria such as Legionella, Mycoplasma and others.
This test provides a comprehensive analysis of multiple respiratory pathogens circulating in the population increasing the chances of early detection and effective treatment of the infection. Also, this examination can be offered for emergencies within one to two hours.
“The respiratory infections in question are transmitted in a similar way and manifest with similar clinical symptoms such as fever, cough, runny nose, sneezing, shortness of breath and chest pain, which makes their clinical diagnosis through symptoms impossible,” NIPD explained.
The Respiratory Virus Test 4 and the 22 Respiratory Infection Test are appropriate for people who show symptoms of respiratory infections, people who have come in contact with people suffering from an infection or people who are concerned about their health, the announcement concluded.